Lecanemab for Early Onset Familial Alzheimer's Disease

Official title

A Real World Study of Lecanemab Treatment in Participants with Early Onset Familial Alzheimer's Disease

Overview

The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing. The study will explore the effects of genetic and hereditary factors on the efficacy of Lecanemab treatment in early-onset familial AD patients.

Primary outcome measures

• Chang of CDR-SB score [Time frame: baseline, 9 month, 18 month]

Secondary outcome measures (12)

• Change of amyloid burden [Time frame: baseline, 9 month, 18 month]
• Change of ADAS-cog score [Time frame: baseline, 9 month, 18 month]
• Change of ADCS-ADL score [Time frame: baseline, 9 month, 18 month]
• Change of MoCA score [Time frame: baseline, 9 month, 18 month]
• Change of BNT score [Time frame: baseline, 9 month, 18 month]
• Change of TMT score [Time frame: baseline, 9 month, 18 month]
• Change of HAMA and HAMD score [Time frame: baseline, 9 month, 18 month]
• Change of biomarkers [Time frame: baseline, 9 month, 18 month]
• Positron emission tomography (PET) [Time frame: baseline, 9 month, 18 month]
• Change of structural MRI [Time frame: baseline, 9 month, 18 month]
• Change of functional MRI [Time frame: baseline, 9 month, 18 month]
• Change of magnetic susceptibility [Time frame: baseline, 9 month, 18 month]

Eligibility criteria

Inclusion criteria

• Age at onset ≤ 65 years, with a minimum age of 18 years; no restriction on gender.
• Diagnosis of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI): Must meet the clinical diagnostic criteria for AD-related MCI and mild AD as defined by the National Institute on Aging and the Alzheimer's Association (NIA-AA) (2011); confirmed Aβ positivity through Aβ-PET/CT, Aβ-PET/MRI, or cerebrospinal fluid testing.
• MMSE ≥ 21 or MoCA ≥ 17 or CDR = 0.5
• No significant signs found in the neurological examination
• Participants must be capable of completing cognitive assessments and other tests.
• Informed consent must be obtained from the participants and their legal guardians, with a dated signature, prior to any operations or tests related to the protocol, committing to comply with the research procedures and cooperate throughout the study process.

Exclusion criteria

• Cognitive decline caused by other reasons: cerebrovascular disease, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, Lewy body dementia, traumatic dementia, other physical and chemical factors (drugs, alcohol, CO, etc.), significant systemic diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (subdural hematoma, brain tumor), endocrine system disorders (thyroid disease, parathyroid disease), and dementia caused by vitamin deficiencies or any other reasons.
• Patients with other unstable diseases, or those who have had a stroke or transient ischemic attack, bleeding disorders, or seizures within the previous 12 months.
• Patients with psychiatric disorders who meet DSM-IV criteria for schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium.
• Patients with unstable or severe heart, lung, liver, kidney, hematological diseases; those with known malignancies or other serious prognoses.
• Exclusion of cerebral amyloid angiopathy-related inflammation/β-amyloid-related cerebral vasculitis (CAAri/ABRA).
• Presence of uncorrectable visual or auditory impairments that prevent completion of relevant assessments or scales.
• Patients who cannot undergo MRI due to claustrophobia, pacemakers, defibrillators, or metal implants.
• MRI findings showing more than four microhemorrhages (diameter < 10 mm), evidence of surface iron deposition, vascular edema, diffuse white matter disease, multiple lacunar strokes, or any strokes involving major vascular regions. Presence of evidence of cerebral contusions, brain softening, cerebral aneurysms, or other vascular malformations, central nervous system (CNS) infections, as well as brain tumors other than meningiomas or arachnoid cysts.
• Patients taking warfarin, vitamin K antagonists, or direct oral anticoagulants (dabigatran, rivaroxaban, edoxaban, apixaban, betrixaban) or heparin; patients receiving thrombolysis; patients with coagulation disorders.
• Pregnant or lactating women.
• Patients deemed unsuitable for use by clinicians apart from the exclusion criteria listed above.
• Patients with severe allergies to lecanemab or any excipients of this product.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model

Cohort

Study locations

China · 15 centers

• Xuanwu Hospital, Capital Medical University — Beijing
• The Second Affiliated Hospital of Guangzhou Medical University — Guangdong
• The Affiliated Hospital of Guizhou Medical University — Guizhou
• Nanjing Brain Hospital — Jiangsu
• Nanjing Drum Tower Hospital — Jiangsu
• Nantong First People's Hospital — Jiangsu
• Huadong Hospital, Fudan University — Shanghai
• Renji Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai
• … and 7 more centers

Identifiers

NCT: NCT06883019 · LEOFAD-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗